Ubrogepant

• CAT Number: R021588
• CAS Number: 1374248-77-7
• Molecular Formula: C29H26F3N5O3
• Molecular Weight: 549.55
• Purity: 98%
• Synonyms: MK-1602; Ubrelvy
• Target: CGRP antagonist
• Target Protein: Q16602
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IC50: CGRP receptors: Ki = 0.067 nmol/L
• IUPAC Name: (3S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2-oxospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide
• InChI: InChI=1S/C29H26F3N5O3/c1-16-20(17-6-3-2-4-7-17)11-22(26(39)37(16)15-29(30,31)32)35-25(38)19-10-18-12-28(13-23(18)34-14-19)21-8-5-9-33-24(21)36-27(28)40/h2-10,14,16,20,22H,11-13,15H2,1H3,(H,35,38)(H,33,36,40)/t16-,20-,22+,28+/m1/s1
• InChIKey: DDOOFTLHJSMHLN-ZQHRPCGSSA-N
• SMILES: C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=CC=CC=C6

Ubrogepant（Cat No.:R021588）is an oral calcitonin gene-related peptide (CGRP) receptor antagonist used for the acute treatment of migraine attacks with or without aura in adults. By blocking CGRP receptors, Ubrogepant interrupts the pathway responsible for migraine pain, vasodilation, and inflammation. Unlike traditional migraine treatments, Ubrogepant is non-vasoconstrictive, making it a safer option for patients with cardiovascular risk factors. Its rapid onset of action provides effective relief from migraine symptoms, offering a well-tolerated alternative for patients seeking non-opioid, non-triptan treatment options for acute migraine management.